Candel Therapeutics
CADL
81 hedge funds and large institutions have $116M invested in Candel Therapeutics in 2025 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 26 increasing their positions, 24 reducing their positions, and 12 closing their positions.
313% more call options, than puts
Call options by funds: $2.96M | Put options by funds: $717K
25% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 12
4% more funds holding
Funds holding: 78 → 81 (+3)
8% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 24
1% less capital invested
Capital invested by funds: $117M → $116M (-$949K)
4.69% less ownership
Funds ownership: 45.98% → 41.29% (-4.7%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$1.46M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.27M |
| 3 |
Millennium Management
New York
|
+$790K |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$677K |
| 5 |
Kovitz Investment Group Partners
Chicago,
Illinois
|
+$458K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$1.8M |
| 2 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$1.37M |
| 3 |
Two Sigma Investments
New York
|
-$1.35M |
| 4 |
Renaissance Technologies
New York
|
-$828K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$748K |
CADL Hedge Fund Activity: Q3 2025 in Review
81 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Candel Therapeutics (CADL) for Q3 2025, worth a combined $116M — down 0.81% from $117M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new CADL positions and 12 closed out — a net gain of 3 holders — while 26 added to existing stakes and 24 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $1.46M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $1.8M sold.
- 81 institutional investors held Candel Therapeutics (CADL) as of Q3 2025, up from 78 in Q2 2025.
- Funds reported $116M of Candel Therapeutics stock for Q3 2025, down 0.81% quarter-over-quarter.
- 15 funds opened new Candel Therapeutics positions in Q3 2025 and 12 closed out, a net change of +3 holders.
- The largest Candel Therapeutics buyer in Q3 2025 was Citadel Advisors, an estimated $1.46M added.
- The largest Candel Therapeutics seller in Q3 2025 was Baker Bros. Advisors, an estimated $1.8M sold.
Based on aggregated 13F filings for Q3 2025.